CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage oncology company focused on chimeric engulfment receptor T-cell, or CER-T, therapy for hematologic malignancies. The company reached Nasdaq through its de-SPAC merger with Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, which completed in early 2024. CERO filed a new S-1 registration statement on December 5, 2025 (accession 0001213900-25-118817), marking continued activity in the public markets as the company advances its pipeline in the cell therapy sector. For the full filing history, current status, sponsor profile, and deal analytics on CERO and hundreds of other SPAC transactions, sign up for complete data at SpacDesk.